– Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval – – Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary ITP – HONG KONG and FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited ("HUTCHMED”) (Nasdaq/AIM:?HCM; HKEX:?13) today announces that the US Food and Drug Administration ("FDA”) has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia ("AIHA”). Sovleplenib is a novel, selective, oral spleen tyrosine kinase ("Syk”) inhibitor. This marks the second Orphan Drug Designation granted by the US…